<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.91010</article-id><article-id pub-id-type="publisher-id">ACM-28558</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190100000_37955299.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  急性缺血性卒中再灌注治疗后血管再闭塞
  Reocclusion after Reperfusion Therapy in Patients with Acute Ischemic Stroke
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>季</surname><given-names>晓康</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谈</surname><given-names>跃</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>昆明医科大学第二附属医院脑血管病科，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2019</year></pub-date><volume>09</volume><issue>01</issue><fpage>51</fpage><lpage>56</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    急性缺血性卒中目前最理想的治疗方法仍然是尽快开通闭塞的血管，恢复血流灌注，拯救更多的缺血半暗带组织。静脉溶栓、桥接取栓及机械取栓是目前较为公认的开通血流再灌注的有效治疗方案。但部分患者再灌注后疗效仍不佳，是由于溶栓后的并发症导致神经功能恶化。其中再灌注治疗后出现血管再闭塞，是严重影响溶栓患者预后的原因之一。本文对再灌注治疗急性脑梗死后血管再闭塞可能发生机制、影响因素和可能防治措施进行综述。
    The most ideal treatment for acute ischemic stroke is still to open the occluded blood vessels as soon as possible and to recover the blood perfusion, so as to save more ischemic penumbra tissue. Intravenous thrombolysis, bridging thrombectomy and mechanical thrombectomy are currently recognized as effective treatment options for reopening blood flow. However, some patients still have poor efficacy after reperfusion, which is due to complications of thrombolysis leading to neurological deterioration. Reocclusion after reperfusion therapy is one of the reasons that seri-ously affect the prognosis of patients with thrombolysis. This article reviews the possible mecha-nism, influencing factors and possible measures of prevention and treatment after reocclusion. 
  
 
</p></abstract><kwd-group><kwd>急性缺血性卒中，溶栓，抗血小板治疗, Acute Ischemic Stroke</kwd><kwd> Thrombolysis</kwd><kwd> Antiplatelet Therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>急性缺血性卒中再灌注治疗后血管再闭塞<sup> </sup></title><p>季晓康<sup>*</sup>，谈跃<sup>#</sup></p><p>昆明医科大学第二附属医院脑血管病科，云南 昆明</p><disp-formula id="hanspub.28558-formula7"><graphic xlink:href="//html.hanspub.org/file/10-1570789x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年12月29日；录用日期：2019年1月14日；发布日期：2019年1月21日</p><disp-formula id="hanspub.28558-formula8"><graphic xlink:href="//html.hanspub.org/file/10-1570789x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>急性缺血性卒中目前最理想的治疗方法仍然是尽快开通闭塞的血管，恢复血流灌注，拯救更多的缺血半暗带组织。静脉溶栓、桥接取栓及机械取栓是目前较为公认的开通血流再灌注的有效治疗方案。但部分患者再灌注后疗效仍不佳，是由于溶栓后的并发症导致神经功能恶化。其中再灌注治疗后出现血管再闭塞，是严重影响溶栓患者预后的原因之一。本文对再灌注治疗急性脑梗死后血管再闭塞可能发生机制、影响因素和可能防治措施进行综述。</p><p>关键词 :急性缺血性卒中，溶栓，抗血小板治疗</p><disp-formula id="hanspub.28558-formula9"><graphic xlink:href="//html.hanspub.org/file/10-1570789x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/10-1570789x8_hanspub.png" /> <img src="//html.hanspub.org/file/10-1570789x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>卒中是导致人类致残和致死的主要病因之一，其中急性缺血性卒中(Acute Ischemic Stroke, AIS)又称脑梗死，是最常见的卒中类型之一，约占全部卒中的60%~80% [<xref ref-type="bibr" rid="hanspub.28558-ref1">1</xref>]。运用重组织型纤溶酶原激活剂(Recombinant Tissue Plasminogen Activator, rtPA)静脉溶栓的时间窗为3~4.5 h，而对于动脉溶栓及机械取栓治疗，前循环梗死的时间窗可延长，分别为6 h和8 h，后循环梗死的时间窗可扩大至24 h [<xref ref-type="bibr" rid="hanspub.28558-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.28558-ref2">2</xref>]。在时间窗内行血管再灌注治疗是治疗急性脑梗死的有效方法，应在时间窗内尽快静脉给予rt-PA溶栓治疗。部分病人予静脉溶栓、动脉溶栓及机械取栓后而再灌注治疗后获益，也有部分病人再灌注治疗后疗效欠佳，这主要与治疗后的血管再通率、并发症引起的神经功能恶化有关。而并发症中血管再闭塞发生率已超过人们熟知的症状性颅内出血(Symptomatic Intracranial Hemorrhage, sICH) [<xref ref-type="bibr" rid="hanspub.28558-ref3">3</xref>]，血管再闭塞患者往往预后不良。</p></sec><sec id="s4"><title>2. 血管再闭塞的定义</title><p>血管再闭塞的定义尚不统一。TIMI分级系统是最早应用于评价急性心肌梗死血管再通的血流评价系统。Andrew [<xref ref-type="bibr" rid="hanspub.28558-ref4">4</xref>] 等将TIMl分级的思想应用于经颅多普勒超声，根据急性缺血性卒中早期的血流速度的特点，发展形成了TIBI (Thrombolysis in Brain Infarction)分级系统。Rubiera [<xref ref-type="bibr" rid="hanspub.28558-ref5">5</xref>] 等将血管再闭塞定义为：在获得最初的血管再通之后，TIBI分级增加 &gt; 1级。Alexandrov和Grotta [<xref ref-type="bibr" rid="hanspub.28558-ref6">6</xref>] 认为，脑缺血溶栓血流分级方法(TIB1分级)增加 ≥ 1级并复查CT排除出血后即可确定血管再闭塞。Grotta [<xref ref-type="bibr" rid="hanspub.28558-ref7">7</xref>] 等将溶栓后NHISS评分降低 ≥ 2分定义为血管再通，在此基础上NIHSS评分再次增高 ≥ 2分定义为血管再闭塞(需经影像学检查排除症状性颅内出血sICH)。Quresh [<xref ref-type="bibr" rid="hanspub.28558-ref8">8</xref>] 采用脑血管造影术将将血管再闭塞定义为在血管内治疗过程中，经过动脉溶栓后起初获得部分或完全再通的血管在原闭塞位置或远端血管发生再次闭塞。血管再闭塞既可以是原始动脉再闭塞，又可以是远端栓塞。“动脉再闭塞”定义为在血管初始再通已实现后的后续再闭塞，远端栓塞被定性地定义为下游血管出现血栓 [<xref ref-type="bibr" rid="hanspub.28558-ref9">9</xref>]。</p></sec><sec id="s5"><title>3. 影响静脉及动脉溶栓后血管再闭塞的因素</title><p>有研究表明，年龄大于75岁、既往抗血小板治疗、基线NHISS评分大于16分、血管再通时间小于60 min、单侧颈内动脉严重狭窄与血管再闭塞相关，其中卒中严重程度和单侧颈动脉严重疾病可独立预测静脉溶栓后患者出现血管再闭塞 [<xref ref-type="bibr" rid="hanspub.28558-ref5">5</xref>]。BAIK [<xref ref-type="bibr" rid="hanspub.28558-ref10">10</xref>] 发现早期再闭塞更容易发生在部分再通的患者中，这可能是由于部分再通的血管仍然存在中到重度的狭窄，产生血流剪切力和湍流，血栓并未完全溶解，残留血栓具有高度致栓性，溶栓暴露了栓子、斑块的表面，成为血栓形成的基础 [<xref ref-type="bibr" rid="hanspub.28558-ref11">11</xref>]。Heo [<xref ref-type="bibr" rid="hanspub.28558-ref12">12</xref>] 也发现发病前服用抗血小板药物溶栓者不易发生再闭塞，可能是因为在溶栓过程中，rt-PA可直接激活血小板，血小板活化在早期血栓再形成中起着关键作用，溶栓前应用阿司匹林等抗血小板药物可抑制这一过程。一些生化指标和基因同样可以预测溶栓后血管再闭塞。CD40基因单核苷酸多态性(rs1883832)和MGP基因单核苷酸多态性为血管再闭塞的独立预测因素 [<xref ref-type="bibr" rid="hanspub.28558-ref13">13</xref>]。TAFI基因(Thr325Ile)与tPA抵抗相关 [<xref ref-type="bibr" rid="hanspub.28558-ref14">14</xref>]，PAI-14G5G基因型与溶栓治疗后再闭塞与转归不良相关 [<xref ref-type="bibr" rid="hanspub.28558-ref15">15</xref>]。国内有研究发现血浆GMP-40增高提示早期血管再闭塞患者体内血小板活化并且活性物质释放而加剧血小板聚集，促使血小板栓子形成，导致血管再闭塞 [<xref ref-type="bibr" rid="hanspub.28558-ref16">16</xref>]。急性缺血性卒中患者动脉溶栓较静脉溶栓治疗可以获得较高的血管再通率，但动脉溶栓后同样可能发生血管再闭塞。基线病情重的患者往往提示大血管闭塞，动脉溶栓后多为部分血管再通，所以基线病情重的患者发生再闭塞的几率高 [<xref ref-type="bibr" rid="hanspub.28558-ref17">17</xref>]。</p></sec><sec id="s6"><title>4. 影响机械取栓后血管再闭塞的因素</title><p>静脉溶栓虽是急性脑梗死患者时间窗内的有效方法，但对于大动脉闭塞的患者再通率较低 [<xref ref-type="bibr" rid="hanspub.28558-ref18">18</xref>]。机械取栓对于大血管闭塞脑梗死患者的有效性已经得到证明 [<xref ref-type="bibr" rid="hanspub.28558-ref19">19</xref>]，但再闭塞同样是影响机械取栓效果的一个重要并发症。机械取栓术后很多因素导致血管再次闭塞。原位血栓(In Stu Thrombosis, IST)形成是在动脉狭窄的基础上因斑块破裂所引起，是颅内动脉粥样硬化梗死的主要原因。国内一些研究发现接受取栓治疗并伴有原位血栓形成的患者更易于发生血管再闭塞，大部分机械取栓中血管再闭塞的发生和原位血栓有关 [<xref ref-type="bibr" rid="hanspub.28558-ref20">20</xref>]。周志国 [<xref ref-type="bibr" rid="hanspub.28558-ref21">21</xref>] 等发现用Solitaire支架取栓次数大于3次，取栓时间窗超过6 h，血管再闭塞比率明显增高，这可能是由于拉栓次数多，血管内膜损伤，暴露出内皮下的胶原，活化血小板和凝血因子XII，内皮下结缔组织内的纤维连接蛋白也有助于血液细胞的纤维蛋白原粘着在暴露的血管壁上，导致血栓形成 [<xref ref-type="bibr" rid="hanspub.28558-ref22">22</xref>]。病变部位血管硬化、血管近心端颈动脉、椎动脉开口狭窄、多次取栓后血管内膜损伤、血管本身缺血再灌注损伤及围手术辅助措施等均是机械取栓术后血管再闭塞的危险因素 [<xref ref-type="bibr" rid="hanspub.28558-ref21">21</xref>]。Qureshi [<xref ref-type="bibr" rid="hanspub.28558-ref23">23</xref>] 等发现机械性操作如支架置入、网套操作、球囊扩张，可导致硬化斑块或内皮细胞的损害，暴露组织因子，激活血小板活性，引起血小板黏附聚集，引起连锁凝血过程，导致再闭塞的发生。机械取栓可造成栓子的逃逸，造成远端血管再闭塞。但有研究发现，远端再闭塞不会造成患者远期的不良预后，反而预示了血管原闭塞部位的成功再通 [<xref ref-type="bibr" rid="hanspub.28558-ref9">9</xref>]。</p></sec><sec id="s7"><title>5. 血管再闭塞的防治</title><sec id="s7_1"><title>5.1. 抗血小板药物和抗凝药物</title><p>血管再闭塞的预防主要是抗血小板药物和抗凝药物。抗血小板药物主要有阿司匹林和氯吡格雷，阿司匹林为COX-2抑制剂，从而抑制花生四烯酸转化为PGG2和PGH2，减少血栓烷A2的合成。血栓烷A2是一种强大的血小板释放及聚集诱导物，抑制血栓烷A2的合成是阿司匹林防止血栓形成的主要作用靶点。硫酸氢氯吡格雷的代谢产物可通过与二磷酸腺苷P2Y<sub>12</sub>。受体不可逆结合，进而干扰血小板活化。抗凝药物主要为低分子肝素钙，低分子肝素钙为Xa因子抑制剂，可抑制凝血系统，预防血栓形成。rt-PA半衰期短，仅有6小时，中国脑血管病防治指南指出溶栓后24h内一般不使用肝素类及阿司匹林类药物，这使得溶栓治疗具有一定的局限性。并且出于对出血性转化(Hemorrhagic Transformation, HT)的担心，抗凝和抗血小板治疗必须在溶栓治疗24 h后开始 [<xref ref-type="bibr" rid="hanspub.28558-ref1">1</xref>]，这使得24 h内对于血管再闭塞的预防性用药处于空白状态。一项总共纳入24项随机对照试验共23,748例患者的Cochrane系统评价 [<xref ref-type="bibr" rid="hanspub.28558-ref24">24</xref>] 显示，抗凝治疗不能降低缺血性卒中患者的病死率或残疾率，但能减少缺血性卒中复发以及降低肺栓塞和深静脉血栓形成风险，但该获益被会症状性颅内出血风险增高所抵消。Sanne M. Zinkstok [<xref ref-type="bibr" rid="hanspub.28558-ref25">25</xref>] 通过在溶栓后90 min给患者静脉注射300 mg阿司匹林发现早期静脉应用阿司匹林不会改善3个月后的临床结局，还会增加症状性颅内出血的风险，这与中国急性缺血性卒中指南相符。然而，近期国内的一些研究如朱立勋 [<xref ref-type="bibr" rid="hanspub.28558-ref26">26</xref>] 等发现应用低分子肝素钙可改善溶栓患者预后并且不会增加溶栓后血管再闭塞患者的出血风险。24 h内的预防性用药的安全性仍值得进一步研究。</p></sec><sec id="s7_2"><title>5.2. 血小板GIIb/IIIa拮抗剂</title><p>血小板IIb/IIIa拮抗剂主要有替罗非班和阿昔单抗。替罗非班是一种选择性非肽类血小板糖蛋白IIb/IIIa拮抗剂，可以抑制血小板聚集，从而预防动脉粥样硬化型脑梗死取栓后IST导致的再闭塞。替罗非班已被证实在在急性中度脑梗死患者中是安全的，并会降低患者5个月后的死亡率 [<xref ref-type="bibr" rid="hanspub.28558-ref27">27</xref>]。有研究发现，在机械取栓后造影，若发现血管再闭塞，再次取栓后动脉内低剂量(0.5 mg)注射替罗非班可以预防再闭塞的发生 [<xref ref-type="bibr" rid="hanspub.28558-ref20">20</xref>]。在接受机械取栓术的AIS患者中，静脉注射替罗非班不会增加症状性颅内出血的发生率并有助于恢复再灌注和改善患者的神经功能预后 [<xref ref-type="bibr" rid="hanspub.28558-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.28558-ref29">29</xref>]。阿昔单抗是经FDA批准的第一个应用于临床的血小板GIIb/IIIa拮抗剂，Lee [<xref ref-type="bibr" rid="hanspub.28558-ref30">30</xref>] 等认为预防性给予阿昔单抗可以减少再闭塞的发生，Heo [<xref ref-type="bibr" rid="hanspub.28558-ref12">12</xref>] 等研究发现阿昔单抗联合rt-PA静脉溶栓可以使再闭塞的血管再通。</p></sec><sec id="s7_3"><title>5.3. 取栓技术的进步和补救性血管内治疗</title><p>取栓技术的进步可以减少机械取栓中栓子脱落造成的远端栓塞。机械取栓后只有动脉再闭塞与患者长期不良预后相关 [<xref ref-type="bibr" rid="hanspub.28558-ref9">9</xref>]，提示在临床中更应注重动脉再闭塞的预防。由于动脉溶栓及静脉溶栓仅能溶解新鲜的血栓，对粥样硬化造成的管腔狭窄无效。需要及时采取血管造影术，完善血管内治疗，以减少再闭塞的发生。周治国 [<xref ref-type="bibr" rid="hanspub.28558-ref21">21</xref>] 认为综合应用Solitaire支架取栓、动脉溶栓、球囊扩张、支架置入及预见性去骨瓣减压、内减压等多模式手术方式，能有效提高支架取栓血管再通率。</p></sec></sec><sec id="s8"><title>6. 结语</title><p>溶栓后血管再闭塞会造成神经功能的损害和更高的住院死亡率 [<xref ref-type="bibr" rid="hanspub.28558-ref30">30</xref>]，早期再闭塞可以引起临床恶化和糟糕预后 [<xref ref-type="bibr" rid="hanspub.28558-ref5">5</xref>]，而机械取栓后血管再闭塞同样导致严重的致残、致死结果并附带巨额的手术及介入材料费用，其严重制约了手术效果 [<xref ref-type="bibr" rid="hanspub.28558-ref21">21</xref>]。由于再灌注治疗后血管再闭塞显著影响预后，对于溶栓后血管再闭塞高危患者识别显得尤为重要。对于高危患者早期使用抗血小板或抗凝治疗或许有效，但使用抗血小板及抗凝治疗的时机尚无定论，溶栓后24 h的安全性用药仍需进一步研究。加强对各种危险因素的控制，有效防止血管再闭塞是保证溶栓及机械取栓治疗效果的重要措施。取栓中应尽量减少取栓次数，减少对血管内膜的损伤。取栓后的残留血管狭窄可行球囊扩张、支架植入桥接治疗。术后联合应用GPIIb/IIIa抑制剂如替罗非班可减少再闭塞发生或治疗再闭塞。</p></sec><sec id="s9"><title>7. 展望</title><p>目前，虽然早期抗血小板治疗是预防血管再闭塞的关键，但对于抗血小板药物的种类选择、使用时机、给药方式等尚未达成共识。并且还没有相关量表或评分能预测急性脑梗死患者再灌注治疗后血管管再闭塞的发生风险，早期对血管再闭塞高危患者使用抗凝治疗及使用时机仍需获得大样本多中心随机对照试验的支持。因此，需要尽快开展高质量临床研究以评估这类患者的风险效益比，让患者在溶栓后24 h内接受更加安全有效的治疗。</p></sec><sec id="s10"><title>文章引用</title><p>季晓康,谈 跃. 急性缺血性卒中再灌注治疗后血管再闭塞Reocclusion after Reperfusion Therapy in Patients with Acute Ischemic Stroke[J]. 临床医学进展, 2019, 09(01): 51-56. https://doi.org/10.12677/ACM.2019.91010</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28558-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组。 中国急性缺血性脑卒中诊治指南2014 [J]. 中华神经科杂志, 2015, 48(4): 246-257.</mixed-citation></ref><ref id="hanspub.28558-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会神经病学分会, 中华医学会神经病学分会神经血管介入协作组, 急性缺血性脑卒中介入诊疗指南撰写组. 中国急性缺血性脑卒中早期血管内介入诊疗指南[J]. 中华神经科杂志, 2015, 48(5): 356-360.</mixed-citation></ref><ref id="hanspub.28558-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue Plasminogen Activator for Acute Ischemic Stroke. New England Journal of Medicine, 333, 1581-1587.</mixed-citation></ref><ref id="hanspub.28558-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Demchuk, A.M., Burgin, W.S., Christou, I., et al. (2001) Thrombolysis in Brain Ischemia (TIBI) Transcranial Droppler Flow Grades Predict Clinical Severity, Early Recovery, and Morality in Patients Treated with Intravenous Tissue Plaminogin Activator. Stroke, 32, 89-93. &lt;br&gt;https://doi.org/10.1161/01.STR.32.1.89</mixed-citation></ref><ref id="hanspub.28558-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Rubiera, M., Alvarez-Sabn, J., Ribo, M., et al. (2005) Preditors of Early Arterial Reocculusion after Tissue Plasminogen Acti-vator-Induced Recanalization in Acute Ischemic Stroke. Stroke, 36, 1452-1456.  
&lt;br&gt;https://doi.org/10.1161/01.STR.0000170711.43405.81</mixed-citation></ref><ref id="hanspub.28558-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Alexandrov, A.V. and Grotta, J.C. (2002) Arterial Reocclusion in Stroke Patients Treated with Intravenous Tissue Plasminogen Activator. Neurology, 59, 862-867. &lt;br&gt;https://doi.org/10.1212/WNL.59.6.862</mixed-citation></ref><ref id="hanspub.28558-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Grotta, J.C., Welch, K.M., Fagan, S.C., et al. (2001) Clinical Deteri-oration Following Improvement in the NINDS rt-PA Stroke Trial. Stroke, 32, 661-668. &lt;br&gt;https://doi.org/10.1161/01.STR.32.3.661</mixed-citation></ref><ref id="hanspub.28558-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Qureshi, A.I., Siddiqui, A.M., Kim S.H., et al. (2004) Reocclusion of Recanalized Ateries during Intra Arterial Thrombolysis for Acute Ischemic Stroke. American Journal of Neuroradi-ology, 25, 322-328.</mixed-citation></ref><ref id="hanspub.28558-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Janjua, N., Alkawi, A., Suri, M.F.K., et al. (2008) Impact of Arterial Reocclusion and Distal Fragmentation during Thrombolysis among Patients with Acute Ischemic Stroke. American Journal of Neuroradiology, 29, 253-258.  
&lt;br&gt;https://doi.org/10.3174/ajnr.A0825</mixed-citation></ref><ref id="hanspub.28558-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Baik, S.K., Oh, S.J., Park, K.-P., et al. (2011) Intra-Arterial Tifofiban Infusion for Partial Recanalization with Stagnant Flow in Hyperacute Cerebral Ischemic Stroke. Interventional Neuro-radiology, 17, 442-451.  
&lt;br&gt;https://doi.org/10.1177/159101991101700408</mixed-citation></ref><ref id="hanspub.28558-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">孙建, 付慧霄, 孙艳军. 应用RT-PA溶栓治疗脑梗死病人溶栓后血管再闭塞的临床特点[J]. 中国老年学杂志, 2016, 4(36): 1868-1869.</mixed-citation></ref><ref id="hanspub.28558-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Heo, J.H., Lee, K.Y., Kim, S.H., et al. (2003) Immediate Reocclusion Following a Successful Thrombolysis in Acute Stroke: A Pilot Study. Neurology, 60, 1684-1687. &lt;br&gt;https://doi.org/10.1212/01.WNL.0000063323.23493.98</mixed-citation></ref><ref id="hanspub.28558-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">del Rio-Espinola, A., Fernan-dez-Cadenas, I., Rubiera, M., et al. (2010) CD40-1C&gt;T Poly Morphism (rs1883832) Is Associated with Brain Vessel Reocclusion after Fibrinolysis in Aschenemic Stroke Patient. Pharmacogenomics, 11, 763-772. &lt;br&gt;https://doi.org/10.2217/pgs.10.44</mixed-citation></ref><ref id="hanspub.28558-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Fernandez-Cadenas, I., Alvarez-Sabin, J., Ribo, M., et al. (2007) Influnce of Tnrombin-Activatable Fibrinolysis Inhibitor and Plasminogin Activator Inhibitor-1 Gene Polymorphisms on Tissue-Type Plasminogen Activator-Induced Recanalization in Ischemic Stroke Patients. Journal of Thrombosis and Haemostasis, 5, 1862-1868.  
&lt;br&gt;https://doi.org/10.1111/j.1538-7836.2007.02665.x</mixed-citation></ref><ref id="hanspub.28558-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Fernandez-Cadenas, I., Rubiera, M., et al. (2010) Poly-morphism Is Associated with Brain Vessel Reocclusion after Successful Fibrinolytic Therapy in Ischemic Stroke Patients. International Journal of Neuroscience, 120, 245-251.  
&lt;br&gt;https://doi.org/10.3109/00207451003597169</mixed-citation></ref><ref id="hanspub.28558-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">李登星. 尿激酶静脉溶栓后早期血管再闭塞与血液凝血、纤溶活性的临床观察[J]. 中国实用神经疾病杂志, 2010, 13(21): 51-53.</mixed-citation></ref><ref id="hanspub.28558-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">付睿, 赵星辉, 黄栋, 等. 急性缺血性脑卒中动脉溶栓中血管再闭塞的临床分析[J]. 实用医学杂志, 2011, 27(20): 3737-3739.</mixed-citation></ref><ref id="hanspub.28558-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Bhatia, R., Hill, M.D., Shobha, N., et al. (2010) Low Rates of Acute Recanalization with Intravenous Recombinant Tissue Plasminogen Acti-vator Inischemic Stroke: Real-World Experience and a Call Foraction. Stroke, 41, 2254-2258.  
&lt;br&gt;https://doi.org/10.1161/STROKEAHA.110.592535</mixed-citation></ref><ref id="hanspub.28558-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Goyal, M., Menon, B.K., Van Zwam, W.H., et al. (2016) Endovascular Thrombectomy after Large-Vessel Ischaemic Stroke: A Meta-Analysis of Individual Patient Data from Five Randomised Trials. The Lancet, 387, 1723-1731.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(16)00163-X</mixed-citation></ref><ref id="hanspub.28558-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">戴征, 李敏, 王怀明, 代齐良, 许剑, 刘新峰. 替罗非班在机械取栓中原位血栓形成导致再闭塞中的应用[J]. 中华神经科杂志, 2017, 50(6): 440-444.</mixed-citation></ref><ref id="hanspub.28558-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">周志国, 陈静, 朱青峰. Solitaire支架机械取栓术后血管再闭塞病因分析及防治策略[J]. 中国医学创新, 2018, 15(16): 5-9.</mixed-citation></ref><ref id="hanspub.28558-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">陈振光, 张发惠, 谢昀, 等. 同种异体骨与血管组织深低温冷藏的时限研究[J]. 中华创伤骨科杂志, 2004, 9(6): 1027-1029.</mixed-citation></ref><ref id="hanspub.28558-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Qureshi, A.I., Siddiqui, A.M., Kim, S.H., et al. (2004) Reocclusion of Recanalized Arteries during Intraarterial Thromholysis for Acute Ischemic Stroke. American Journal of Neuroradiology, 25, 322-328.</mixed-citation></ref><ref id="hanspub.28558-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Sandercock, P.A., Counsell, C. and Kana, E.J. (2015) Anticoagn Lants for Acute Ischemic Stroke. Cochrane Database of Systematic Reviews, 12, CD000024.</mixed-citation></ref><ref id="hanspub.28558-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Zinkstok, S.M., Roos, Y.B. and ARTIS Investigators (2012) Early Administration of Aspirin in Patients Treated with Alteplase for Acute Ischaemic Stroke: A Randomized Controlled Trial. The Lancet, 380, 731-737.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(12)60949-0</mixed-citation></ref><ref id="hanspub.28558-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">朱立勋, 耿瑞慧, 陆学胜, 李克良, 丁素菊. 急性脑梗死阿替普酶静脉溶栓后血管再闭塞应用低分子肝素钙的价值[J]. 武警医学, 2015, 26(6): 555-557, 562.</mixed-citation></ref><ref id="hanspub.28558-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Siebler, M., Hennerici, M.G., Schneider, D., von Reutern, G.M., Seitz, R.J., Rother, J., et al. (2011) Safety of Tirofiban in Acute Ischemic Stroke: The SaTIS Trial. Stroke, 42, 2388-2392. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.110.599662</mixed-citation></ref><ref id="hanspub.28558-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, W., Che, R. and Shang, S. (2017) Low-Dose Tiro-fiban Improves Functional Outcome in Acute Ischemic Stroke Patients Treated with Endovascular Thrombectomy. Stroke, 48, 3289-3294.  
&lt;br&gt;https://doi.org/10.1161/STROKEAHA.117.019193</mixed-citation></ref><ref id="hanspub.28558-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, H., Zhang, J., Gu, D., et al. (2017) Tirofiban Fa-cilitates the Reperfusion Process during Endovascular Thrombectomy in ICAS. Experimental and Therapeutic Medicine, 14, 3314-3318. &lt;br&gt;https://doi.org/10.3892/etm.2017.4856</mixed-citation></ref><ref id="hanspub.28558-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Lee, K.Y., Heo, J.H., Lee, S.I., et al. (2001) Rescue Treatment with Abciximab in Acute Ischemic Stroke. Neurology, 56, 1585-1587. &lt;br&gt;https://doi.org/10.1212/WNL.56.11.1585</mixed-citation></ref></ref-list></back></article>